TICKERNERD
Menu
MISTMISTHealthcare · Biotechnology

MIST Stock Forecast: Milestone Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.06
+2.43% on the day

The 7 Wall Street analysts covering Milestone Pharmaceuticals, Inc. hold a median 12-month price target of $7 — +563.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$131.3M
Ticker Nerd rank
18 / 100
Median analyst target
$7.00
Analysts covering
7
Total return, dividends reinvested
1W
−4.1%
1M
−14.2%
YTD
−47.8%
1Y
−38.3%
From 52W high
−64.2%
From 52W low
+4.5%
$1.01
$2.95
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MIST stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Milestone Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
18 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
73
Accruals
51
Revisions
46
Quality
40
Volatility
34
Growth
32
Momentum
20
Value
20
Issuance
4

Size (73): Smaller than most of the companies we track.

Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MIST stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MIST, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26MISTHigh $8.00Median $7.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $2.00Median $7.00High $8.00

The green dot is the last close — the median target sits +563.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Aug 2026Cantor FitzgeraldInitiatesOverweight$3.00
14 May 2026Wells FargoMaintainsOverweight$8.00 → $7.00
6 Jan 2026HC Wainwright & Co.ReiteratesBuy—
16 Dec 2025Wells FargoMaintainsOverweight—
15 Dec 2025HC Wainwright & Co.MaintainsBuy—
15 Dec 2025TD CowenUpgradeBuy—
11 Sept 2025Wells FargoInitiatesOverweight—
5 June 2025HC Wainwright & Co.AssumesBuy$5.00
1 Apr 2025HC Wainwright & Co.MaintainsBuy—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
17 Mar 2025HC Wainwright & Co.ReiteratesBuy—
28 Feb 2025HC Wainwright & Co.ReiteratesBuy—
27 Jan 2025HC Wainwright & Co.ReiteratesBuy—
14 Oct 2024HC Wainwright & Co.ReiteratesBuy—
22 Aug 2024HC Wainwright & Co.ReiteratesBuy—
22 Aug 2024Rodman & RenshawInitiatesBuy—
1 July 2024HC Wainwright & Co.ReiteratesBuy—
30 May 2024HC Wainwright & Co.ReiteratesBuy—
16 May 2024HC Wainwright & Co.ReiteratesBuy—
22 Mar 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MIST appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MIST analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Milestone Pharmaceuticals, Inc. (MIST) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.4×

Cheaper than 84% of US stocks

Price / sales
56.1×

Cheaper than 5% of US stocks

Price / book
3.9×

Cheaper than 28% of US stocks

EV / EBITDA
−1.5×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
−84.6%

Higher than 2% of US stocks

Earnings growth (YoY)
—
Gross margin
94.1%

Higher than 98% of US stocks

Operating margin
−4585.0%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−35522.6%

Higher than 1% of US stocks

Return on assets
−42.8%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MIST vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MISTMilestone Pharmaceuticals, Inc.$131.3M
18
VTVTvTv Therapeutics, Inc.$131.0M
77
CBUSCibus, Inc.$129.5M
33
BDTXBlack Diamond Therapeutics, Inc.$126.6M
55
VANIVivani Medical, Inc.$124.5M
40
ANIXAnixa Biosciences, Inc.$124.4M
85
GUTSFractyl Health, Inc.$123.7M
30

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Milestone Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MIST news & analysis

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

GlobeNewsWire · 21 Aug 2026positive

Milestone Pharmaceuticals announced the initiation of its pivotal Phase 3 trial (ReVeRA-301) of etripamil nasal spray for the self-administered treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR). The trial is evaluating the same 70 mg repeat-dose regimen that is FDA approved for paroxysmal supraventricular tachycardia (PSVT).

Why it matters — This advances a new, potentially significant indication for etripamil beyond its approved PSVT use, expanding Milestone's pipeline and commercial opportunity.

Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound

Seeking Alpha · 18 Aug 2026negative

Milestone Pharmaceuticals was reiterated as a 'Sell' by Seeking Alpha, citing weak CARDAMYST differentiation and poor commercial uptake against low-cost generics. Q2 revenue was $559K on over 1,200 scripts, with only ~20% of the PSVT market covered, while cash fell to $170M, liabilities doubled to $163M, and equity dropped to $18M amid a $39M first-half cash burn.

Why it matters — A MIST watcher would care because the report highlights deteriorating financial health, heavy discounting, minimal payer coverage, and compounding royalty debt that raise concerns about the company's commercial viability and balance-sheet position.

Milestone Pharmaceuticals Inc. (MIST) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

Milestone Pharmaceuticals Inc. (MIST) held its Q2 2026 earnings call, with the transcript published on Seeking Alpha. The call covers the company's second-quarter 2026 financial results and business updates.

Why it matters — The earnings call transcript provides MIST investors and watchers with the company's official Q2 2026 financial performance and management commentary.

Milestone Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 12 Aug 2026neutral

Milestone Pharmaceuticals reported early commercial traction for CARDAMYST following its mid-February launch and is advancing a pivotal Phase III study of etripamil in atrial fibrillation with rapid ventricular rate.

Why it matters — The update provides investors with initial signs of CARDAMYST adoption post-launch and a clear view of the company's next clinical milestone in a major indication.

Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 12 Aug 2026negative

Milestone Pharmaceuticals reported a second-quarter loss of $0.21 per share, wider than the Zacks Consensus Estimate of a $0.18 loss and larger than the $0.20 per share loss posted a year ago. The company's results lagged revenue estimates.

Why it matters — The wider-than-expected quarterly loss indicates the company's recent financial performance fell short of analyst projections.

FAQ

Frequently asked questions about MIST stock

What is the MIST stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Milestone Pharmaceuticals, Inc. have a median 12-month price target of $7, with estimates ranging from $2 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MIST stock a buy right now?

Of the 7 analysts covering Milestone Pharmaceuticals, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Milestone Pharmaceuticals, Inc. 18 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MIST?

As at 22 Aug 2026, Milestone Pharmaceuticals, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (73 of 100).

Will MIST stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +563.5% from the last close, and Ticker Nerd's factor model ranks Milestone Pharmaceuticals, Inc. 18 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MIST stock forecast for 2030?

No analyst covering Milestone Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MIST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $8 over the next 12 months.

How has MIST stock performed over the past year?

Milestone Pharmaceuticals, Inc. returned -38.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Milestone Pharmaceuticals, Inc. do?

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for episodic cardiovascular conditions. The company's lead product, etripamil, is a calcium channel blocker formulated as a rapid-onset nasal spray designed for patient self-administration.

What is the latest news on MIST?

The most recent item we track (GlobeNewsWire, 21 Aug 2026): "Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)". Milestone Pharmaceuticals announced the initiation of its pivotal Phase 3 trial (ReVeRA-301) of etripamil nasal spray for the self-administered treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR). The trial is evaluating the same 70 mg repeat-dose regimen that is FDA approved for paroxysmal supraventricular tachycardia (PSVT).

Company

About Milestone Pharmaceuticals, Inc.

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for episodic cardiovascular conditions. The company's lead product, etripamil, is a calcium channel blocker formulated as a rapid-onset nasal spray designed for patient self-administration. Etripamil is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to normal heart rhythm in adults. Beyond PSVT, Milestone is conducting clinical investigations into etripamil's potential for treating atrial fibrillation with rapid ventricular rate (AFib-RVR). The company operates with a lean organizational structure, emphasizing efficient spending on research and development rather than overhead costs. Milestone's leadership team comprises experienced pharmaceutical executives with expertise in cardiovascular medicine, clinical drug development, regulatory affairs, and commercialization. Headquartered in Montreal, Canada, the company was founded in 2003 and remains dedicated to addressing unmet needs in the treatment of acute and episodic cardiovascular conditions.

CEO Mr. Joseph G. Oliveto M.B.A. · 38 employees · Canada · https://www.milestonepharma.com